Here's why Regeneron (REGN) and Bayer's (BAYRY) fast growing Eylea for AMD is on target to eclipse $2 billion in global sales this year. Few drugs become multi-billion blockbusters, but those that do ...

German pharmaceutical giant Bayer BAYRY. Shares have skyrocketed 121.6% over the past year compared with the industry’s gain ...

Regeneron has had its hands full this year contending with regulatory | Alvotech and Teva's Eylea biosimilar has been under FDA review for much of this year. Back in February, the companies said they ...

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...

When Regeneron snagged an FDA nod for eye drug Eylea in diabetic retinopathy in 2019, the agency opted against approving a 16-week dosing schedule despite positive data from a pivotal trial. Now, the ...

TARRYTOWN, N.Y., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the first presentation of positive two-year (96 weeks) results from the pivotal PULSAR ...

The U.S. Food and Drug Administration has accepted for Priority Review Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) ...

Updated versions of best-selling drugs may mitigate some of the impact of patent cliff losses, but the strategy behind the ...

Another attempt to take on Regeneron and Bayer's juggernaut Eylea is struggling in the clinic. This time, it’s Ribomic’s wet age-related macular degeneration (AMD) therapy RBM-007. The small biotech ...

According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in ...

On July 26, 2012, Regeneron Pharmaceuticals, Inc. (REGN) announced results for the second quarter ending June 30, 2012. The company posted a 182.2% year-to-year increase on total revenues of $304.3 ...